ANAPLASTIC LARGE-CELL LYMPHOMA

This adverse event was reported 236 times

ANAPLASTIC LARGE-CELL LYMPHOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 BRENTUXIMAB VEDOTIN 86 0.0083
1 ROMIDEPSIN 8 0.0047
2 L-ARGININE 1 0.0028
3 SODIUM PHENYLBUTYRATE 1 0.0024
4 BRIGATINIB 6 0.0016
5 MARAVIROC 3 0.0013
6 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE 1 0.0010
7 GLYCEROL PHENYLBUTYRATE 1 0.0007
8 TESTOSTERONE ENANTHATE 1 0.0006
9 CEFUROXIME AXETIL 2 0.0006
See all drugs enriched for association with ANAPLASTIC LARGE-CELL LYMPHOMA

ANAPLASTIC LARGE-CELL LYMPHOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD30-directed Immunoconjugate [EPC] 86 0.0083
1 CCR5 Co-receptor Antagonist [EPC] 3 0.0013
2 Monobactam Antibacterial [EPC] 1 0.0004
3 Anthelmintic [EPC] 1 0.0003
4 CD33-directed Immunoconjugate [EPC] 1 0.0003
5 Topoisomerase Inhibitor [EPC] 16 0.0002
6 Antimalarial [EPC] 2 0.0002
7 Antiprotozoal [EPC] 2 0.0002
8 Alkylating Drug [EPC] 41 0.0002
9 Purine Antimetabolite [EPC] 15 0.0002
See all drug classes enriched for association with ANAPLASTIC LARGE-CELL LYMPHOMA